107 Days
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
107 Daysالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
107 DaysReady to play
Ready to play
An international clinical study has revealed that a new injection called "Amivantamab" showed promising results in reducing or eliminating tumors in patients with head and neck cancer who did not respond to traditional treatments. The study was conducted on 102 patients across 11 countries and resulted in tumor size reduction in 43 of them, with 15 patients completely clearing their tumors. Developed by Johnson & Johnson, this medication works by inhibiting growth receptors and helping the immune system attack the tumor. It is administered subcutaneously rather than intravenously. Currently, additional studies are underway to evaluate its effectiveness in other types of cancers such as lung, colon, and stomach cancers.
Notice: This Is an AI-Generated Summary
Comments (0)